The activin and follistatin balance has been shown to be dysregulated in numerous solid tumors, such as prostate cancer and hepatocarcinogenesis [37,38] and the development of resistance to TGFβ growth inhibition is a key event in tumor progression [37,25]. This evidence concerns the gene FST and prostate cancer.